Ultragenyx Pharmaceutical stock faces securities fraud class action after clinical trial setback

Ultragenyx Pharmaceutical (ISIN: US74930A1043) shares plunged 42% in late 2025 following disappointing Phase III data for setrusumab in osteogenesis imperfecta. Investors now have until April 6, 2026, to lead a class action lawsuit alleging misleading statements on the drug's efficacy. DACH investors should monitor this rare disease biotech amid legal and pipeline risks.

Ultragenyx Pharmaceutical stock has come under intense pressure following a sharp decline triggered by clinical trial results that failed to meet expectations. On December 26, 2025, the company disclosed Phase III data for setrusumab, its lead candidate for osteogenesis imperfecta (OI), showing increased bone density but no significant reduction in fracture rates. The Ultragenyx Pharmaceutical stock, listed on NASDAQ in USD, fell approximately 42%, from $34.19 to $19.72 per share on NASDAQ in USD by December 29, 2025. This event has sparked multiple securities fraud class action lawsuits, with a lead plaintiff deadline of April 6, 2026.

As of: 20.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – Specializing in rare disease therapies and clinical pipeline risks for European investors.

Clinical Setback Shakes Investor Confidence

Ultragenyx Pharmaceutical focuses on therapies for rare genetic diseases, with setrusumab targeting OI, a brittle bone disorder affecting about 1 in 15,000 to 20,000 births. The Phase III Orbit and Cosmic studies aimed to demonstrate that setrusumab's bone density gains would translate to fewer fractures. Instead, results revealed no clear correlation, undermining prior management optimism.

Company statements had emphasized the drug's potential to reduce annualized fracture rates, citing robust study designs to minimize variability. Investors reacted swiftly, driving the NASDAQ-listed Ultragenyx Pharmaceutical stock down sharply in USD terms. This miss highlights common biotech pitfalls where surrogate endpoints like bone density fail to predict clinical outcomes.

For DACH investors, familiar with rigorous EMA standards, this underscores the high attrition in late-stage rare disease trials. German-speaking markets have growing exposure to US biotechs via platforms like Trade Republic and Scalable Capital.

The stock's volatility reflects broader biotech sector dynamics, where positive Phase II data often overpromise Phase III success. Ultragenyx now faces recalibrated expectations across its pipeline.

Class Action Lawsuits Gain Momentum

Several law firms, including Rosen Law Firm, Pomerantz LLP, and The Gross Law Firm, have issued notices for investors who bought Ultragenyx Pharmaceutical stock between August 3, 2023, and December 26, 2025. Allegations center on materially false statements about setrusumab's fracture rate reduction potential and study protocol risks.

Lawsuits claim management concealed that bone density increases did not reliably lower fractures, leading to artificially inflated share prices. The Ultragenyx Pharmaceutical stock on NASDAQ in USD dropped $14.47, or 42.32%, to close at $19.72 on December 29, 2025. Lead plaintiff motions are due April 6, 2026, in the Southern District of New York.

These actions are standard post-disappointment in biopharma, recovering funds for affected shareholders without upfront costs via contingency fees. Recent filings on March 19-20, 2026, signal active litigation.

DACH investors holding via brokers like Consorsbank or Comdirect should review purchase dates within the class period for potential recovery.

Pipeline Beyond Setrusumab: Remaining Catalysts

Ultragenyx's portfolio includes approved drugs like Crysvita for X-linked hypophosphatemia and Mepsevii for MPS VII, generating revenue amid cash burn. Setrusumab was a high-conviction asset partnered with Mereo BioPharma, but top-line data forced a strategic pivot.

Other assets in development target glycine encephalopathy (UX701) and Friedreich's ataxia (UX111). Analysts maintain a Moderate Buy rating with a consensus price target implying substantial upside from recent lows, though earnings remain negative at expected losses narrowing from ($5.18) to ($3.22) per share.

The P/B ratio stands elevated, reflecting biotech valuations tied to future milestones rather than current profitability. Short interest has eased, suggesting improving sentiment.

For rare disease specialists, Ultragenyx's focus aligns with Europe's orphan drug incentives, including market exclusivity and pricing support.

Risks and Legal Overhang for Investors

Litigation poses immediate risks, including management distraction, legal costs, and potential settlements eroding cash reserves. Ultragenyx reported quarterly EPS beating estimates but with ongoing losses; sustained pressure could strain finances.

Pipeline execution remains critical—further trial failures could compound the selloff. Regulatory hurdles for OI therapies demand robust fracture data, now in question for setrusumab. Competition in rare bone disorders adds pricing pressure.

Macro factors like interest rates impact biotech funding, with Ultragenyx's market cap around $3 billion post-drop. Investors face dilution risks from capital raises.

Why DACH Investors Should Watch Closely

German, Austrian, and Swiss investors increasingly allocate to US biotechs for diversification, with Ultragenyx accessible via Xetra or direct NASDAQ access. Rare disease focus resonates with Europe's strong orphan drug framework, potentially aiding EU approvals.

Post-drop, the stock trades at depressed levels on NASDAQ in USD, offering entry for risk-tolerant portfolios. Analyst targets suggest recovery potential if pipeline delivers. DACH funds like those from Deutsche Bank or UBS have biotech exposure warranting review.

Legal deadlines provide a near-term catalyst; positive resolutions could lift sentiment. Currency hedging via EUR/USD forwards mitigates FX risk for continental holders.

Strategic Outlook and Valuation Considerations

Ultragenyx must now prioritize cost control and alternative readouts. Revenue growth from approved products supports runway, but setrusumab's fate—possible label tweaks or abandonment—looms large.

Valuation metrics show negative P/E but improving earnings trajectory. Compared to peers, the dip creates asymmetry for upside. Long-term, rare disease markets expand with better diagnostics.

DACH investors benefit from tax-advantaged wrappers like Depot models, positioning for volatility plays.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.